Scancell (LON:SCLP) Share Price Passes Below 200-Day Moving Average – What’s Next?

Scancell Holdings plc (LON:SCLP) shares passed below its 200-day moving average during trading on Friday . The stock has a 200-day moving average of GBX 9.85 and traded as low as GBX 9.30. Scancell shares last traded at GBX 9.55, with a volume of 2,537,865 shares trading hands.

Scancell Price Performance

The company has a market cap of £99.11 million, a PE ratio of -7.58 and a beta of 0.35. The company has a quick ratio of 13.01, a current ratio of 3.42 and a debt-to-equity ratio of -566.79. The firm has a 50 day simple moving average of GBX 9.74 and a 200-day simple moving average of GBX 9.86.

Scancell (LON:SCLP) last released its quarterly earnings results on Thursday, September 11th. The company reported GBX (1.26) earnings per share for the quarter. As a group, research analysts predict that Scancell Holdings plc will post -2.5361112 earnings per share for the current fiscal year.

Insider Activity

In related news, insider Martin Diggle acquired 3,150,000 shares of the business’s stock in a transaction dated Friday, September 12th. The shares were purchased at an average price of GBX 9 per share, for a total transaction of £283,500. Insiders own 15.45% of the company’s stock.

About Scancell

Scancell (LSE:SCLP) is a clinical stage company leveraging two proprietary platforms, Immunobody® and Moditope®, to develop targeted off-the-shelf, patient-accessible active immunotherapies for a cancer-free future. The lead product iSCIB1+ is an Immunobody® DNA active immunotherapy that has demonstrated monotherapy activity in adjuvant melanoma.